Treatment for Relapsed/Refractory Acute Myeloid Leukemia
Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) have a poor prognosis and treatment remains challenging. For the majority of r/r patients, allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment approach. Salvage therapy is given in order to r...
Main Authors: | Felicitas Thol, Michael Heuser |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000572 |
Similar Items
-
Fusion genes in acute myeloid leukemia: do acute myeloid leukemia diagnostics need to fuse with RNA-sequencing?
by: Felicitas Thol
Published: (2021-06-01) -
Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia
by: Rabia Shahswar, et al.
Published: (2023-07-01) -
Treatment of pediatric relapsed and refractory acute myeloid leukemia
by: F. A. Makhacheva, et al.
Published: (2023-05-01) -
Can we forecast induction failure in acute myeloid leukemia?
by: Felicitas Thol
Published: (2018-03-01) -
DNMT3A mutations are rare in childhood acute myeloid leukemia
by: Felicitas Thol, et al.
Published: (2011-08-01)